Recent Finacing
Recent Raise
Haystack Oncology develops an ultrasensitive, tumor-informed ctDNA MRD diagnostic using low-error NGS chemistry and a tissue-informed whole-exome sequencing workflow to generate personalized liquid-biopsy tests.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
